<DOC>
	<DOC>NCT01009216</DOC>
	<brief_summary>The objectives of this study are to assess the cerebral spinal fluid (CSF) pharmacokinetics and the plasma/CSF pharmacokinetic/pharmacodynamic relationship of ABT-384 in healthy male volunteers.</brief_summary>
	<brief_title>A Study of ABT-384 Levels and Pharmacodynamic Activity Measured in Cerebrospinal Fluid</brief_title>
	<detailed_description />
	<criteria>Age is between 18 and 55 years Judged to be in a condition of general good health based on the results of medical history, physical examination, vital signs, laboratory profile and a 12lead ECG Use of protocolprohibited medications within 2 weeks prior to study drug administration. Positive urine drug screen for nonprescribed drugs of abuse including alcohol. Receipt of any drug depot by injection within 30 days prior to study drug administration. Receipt of any investigational product within 6 weeks prior to study drug administration. History of significant sensitivity or allergy to any drug. History of drug or alcohol abuse. Positive test result for HAV, HBsAg, HCV or HIV. Donation or loss of 550 mL or more blood volume or receipt of any blood product within 3 months prior to study drug administration. Contraindication for lumbar puncture (e.g., lumbar scoliosis, coagulopathy, infected skin at puncture site) Current enrollment in another clinical study.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacology</keyword>
	<keyword>Drug Safety</keyword>
	<keyword>Phase 1 Clinical Trials</keyword>
</DOC>